Vaxcyte beats, highlights positive Phase 3 OPUS-1 data
Vaxcyte beats fiscal Q3 2026 estimates with non-GAAP EPS $-1.99 and highlights positive Phase 3 OPUS-1 data
- Fiscal Q3 2026 non-GAAP EPS was $-1.99, a wider loss, down 28% YoY but beating analyst estimates.
- Fiscal Q3 2026 revenue was $0, beating revenue estimates alongside the non-GAAP EPS outperformance.
- Company reported $3.4B pro forma cash as part of its broader business update to investors.
- Company targets a 2028 BLA filing for VAX-31 after reporting positive Phase 3 OPUS-1 data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.